• Germany: Position paper on the WHO 2030 HPV target released

    Published together with the Hepatitis B & C Public Policy Association, the German Liver Foundation the paper calls in particular for the support of vulnerable populations.

  • Neoadjuvant hormonal therapy looks promising in high-risk prostate cancer

    Degarelix plus apalutamide outperformed degarelix alone in high-risk prostate cancer patients who were to receive radical prostatectomy.

  • Worse psychological symptoms in IBD patients with concomitant fibromyalgia

    The study also revealed an 8.7% fibromyalgia prevalence in IBD patients; higher than the prevalence in the general population of 2–3%.

  • Burnout: Emergency physicians worldwide at the limit

    In this interview, Dr. Abdo Khoury addresses a global survey revealed that 62% of emergency medicine staff have been diagnosed with burnout, and how this unfolded

  • Methenamine hippurate: Non-inferiority to antibiotics in recurrent UTIs

    The non-antibiotic preventive methenamine hippurate displayed non-inferiority to daily low-dose prophylactic antibiotics in women with recurrent UTIs.

  • SUI: Mini-slings non-inferior to standard mid-urethral slings

    Single-incision mini-slings were found to be non-inferior to standard mid-urethral slings in women with stress urinary incontinence (SUI).

  • High morbidity in pregnant lupus patients and their unborns

    Pregnancy in SLE have a 3-fold risk of fetal intrauterine growth restriction and 2-fold premature birth risk compared with healthy women.

  • Fewer complications with robotic surgery in renal cancer

    Less complication rates were observed with robotic surgery versus open surgery in patients with intermediate or high complexity renal tumours.

  • Tapering TNF blockers in axSpA and PsA: a successful approach

    In both psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), a T2T TNF-blocker tapering strategy showed to be non-inferior to a T2T strategy.

  • KEYNOTE-564 trial: Updated results for pembrolizumab

    Patients with intermediate-high- or high-risk renal cell carcinoma continued to benefit from pembrolizumab compared with placebo, updated results show.

  • Ukraine: Always looking east

    We ask Ukrainian nurse Romanna Markiv about her life and the future she envisions, as well as the patient care she tirelessly provides in the city of Lviv.

  • Nightmares in urology, open surgery, and robotics

    Dr Tim O'Brien discusses tough medical experiences, while Dr Carlo Bravi argues why young urologists should learn open surgery, despite robotic surgery.

  • Unexpected comorbidity in patients with knee and hip osteoarthritis

    A study revealed that osteoarthritis is associated with a wide variety of diseases previously thought to be unrelated, such as anaemia and thromboembolic disease.

  • Prof. Vassillios Fanos on Metabolomics and Microbiomics

    Prof. Fanos, addresses how COVID-19, AI, Big Data and the future of medicine may impact our relation with the microbiome.

  • Fitness trackers show low physical activity in musculoskeletal disease patients

    Musculoskeletal disease patients manage moderate-to-vigorous physical training, but fail the recommended daily steps.

  • France: Junior mountaineers seek physicians

    “À Chacun Son Everest!” organises trips that are of great inspiration for the children and women in remission joining; and for the physicians travelling with them.

  • Bladder cancer: Robotic surgery shortens post-op hospital stays

    Post-surgery hospital stay was much shorter for bladder cancer patients after full robotic radical cystectomy over those treated with open surgery.

  • Sexual dysfunction prevalent in RA and PsA patients

    According to a Spanish study, patients with rheumatoid arthritis and psoriatic arthritis have a markedly deteriorated sexual life compared with a healthy population.

  • IL-6 inhibition successful in polymyalgia rheumatica

    Sarilumab demonstrated positive results in a phase 3 trial for PMR patients. More participants reached sustained remission and reduced flare risk.

  • Treatment with bimekizumab beneficial in psoriatic arthritis

    The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a PsA therapy.

  • 30 |
  • 31 |
  • 32 |
  • 33 |
  • 34 |
  • 35 |
  • 36 |
  • 37 |
  • 38 |
  • 39 |
  • 40 |